Related Experiment Video

Updated: Apr 28, 2026

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

856

Signaling mechanisms that suppress the cytostatic actions of rapamycin

Stephan C Jahn1, Mary E Law1, Patrick E Corsino1

  • 1Department of Pharmacology and Therapeutics, University of Florida, Gainesville, Florida, United States of America; University of Florida-Health Cancer Center, University of Florida, Gainesville, Florida, United States of America.

Plos One
|June 14, 2014
PubMed

Insights

Rapamycin and its analogs show limited cancer treatment success due to resistance. This study reveals that TGFβ absence and HGF/Akt signaling can cause resistance, suggesting new biomarkers and combination therapies for improved efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Rapamycin and its analogs (e.g., Everolimus, Temsirolimus) are approved cancer treatments but exhibit variable efficacy.
  • Some tumors are resistant to rapamycin, and the underlying mechanisms remain largely unknown.

Purpose of the Study:

  • To elucidate novel cell-signaling mechanisms contributing to rapamycin resistance in cancer.
  • To identify potential biomarkers for predicting patient response to rapamycin-based therapies.

Main Methods:

  • Investigated the role of TGFβ signaling in rapamycin response.
  • Analyzed the effects of rapamycin and analogs on HGF-induced mitogenic signaling and Akt activation in cancer cell lines.

Main Results:

  • Absence of TGFβ signaling was identified as a mechanism conferring resistance to rapamycin.
  • Rapamycin treatment potentiated HGF-induced proliferation and stimulated the pro-survival kinase Akt in certain cancer cell lines.

Conclusions:

  • Rapamycin's effectiveness is influenced by specific signaling pathways, including TGFβ, HGF, and Akt.
  • Findings suggest potential biomarkers for predicting treatment responsiveness and highlight opportunities for combination therapies to enhance rapalog efficacy.

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

16.2K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

8.9K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.7K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K